Enliven Therapeutics (ELVN) Institutional Ownership $20.27 -0.09 (-0.44%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$20.27 0.00 (0.00%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Enliven Therapeutics (NASDAQ:ELVN)CurrentInstitutional OwnershipPercentage95.08%Number ofInstitutional Buyers(last 12 months)66TotalInstitutional Inflows(last 12 months)$207.52MNumber ofInstitutional Sellers(last 12 months)38TotalInstitutional Outflows(last 12 months)$90.81M Get ELVN Insider Trade Alerts Want to know when executives and insiders are buying or selling Enliven Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data ELVN Institutional Buying and Selling by Quarter Enliven Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Tower Research Capital LLC TRC 5,286$106K0.0%+194.3%0.009% 8/15/2025 Duquesne Family Office LLC463,000$9.29M0.2%N/A0.782% 8/15/2025 BNP Paribas Financial Markets3,722$75K0.0%+33.3%0.008% 8/15/2025 Bank of America Corp DE24,508$492K0.0%+20.0%0.050% 8/15/2025 5AM Venture Management LLC772,477$15.50M6.0%-41.6%1.574% 8/15/2025 Adage Capital Partners GP L.L.C.96,000$1.93M0.0%-78.7%0.196% 8/15/2025 Ameriprise Financial Inc.59,244$1.19M0.0%+150.4%0.121% 8/14/2025 Commodore Capital LP4,692,809$94.14M6.6%+0.4%9.563% 8/14/2025 TCG Crossover Management LLC498,000$9.99M1.1%N/A1.015% 8/14/2025 Jane Street Group LLC56,981$1.14M0.0%+94.1%0.116% Get the Latest News and Ratings for ELVN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/14/2025 California State Teachers Retirement System20,330$408K0.0%-2.8%0.041% 8/14/2025 MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.17,656$354K0.0%-18.7%0.036% 8/14/2025 The Manufacturers Life Insurance Company 44,151$886K0.0%+242.4%0.090% 8/14/2025 HighVista Strategies LLC141,516$2.84M1.0%+25.8%0.288% 8/14/2025 Federated Hermes Inc.16,098$323K0.0%-76.7%0.033% 8/13/2025 Affinity Asset Advisors LLC400,000$8.02M1.1%N/A0.815% 8/13/2025 Tema Etfs LLC32,579$654K0.2%+37.8%0.066% 8/13/2025 Marshall Wace LLP333,333$6.69M0.0%+2,886.9%0.679% 8/13/2025 Invesco Ltd.21,957$440K0.0%+4.3%0.045% 8/13/2025 Quantbot Technologies LP4,477$90K0.0%+47.1%0.009% 8/13/2025 Virtus Investment Advisers LLC4,783$96K0.0%-33.0%0.010% 8/13/2025 Russell Investments Group Ltd.29,547$593K0.0%-72.0%0.060% 8/12/2025 XTX Topco Ltd11,362$228K0.0%-48.0%0.023% 8/12/2025 Rhumbline Advisers50,280$1.01M0.0%-4.2%0.102% 8/12/2025 Franklin Resources Inc.430,240$8.63M0.0%+2,029.3%0.877% 8/12/2025 Legal & General Group Plc32,225$646K0.0%+52.2%0.066% 8/12/2025 JPMorgan Chase & Co.19,064$382K0.0%-12.4%0.039% 8/12/2025 Swiss National Bank61,873$1.24M0.0%+47.8%0.126% 8/11/2025 Patient Square Capital LP245,838$4.93M1.8%-3.2%0.501% 8/8/2025 Intech Investment Management LLC14,502$291K0.0%-27.9%0.030% 8/8/2025 SG Americas Securities LLC36,373$730K0.0%+177.4%0.074% 8/8/2025 Candriam S.C.A.416,650$8.36M0.0%N/A0.849% 8/8/2025 Geode Capital Management LLC882,753$17.71M0.0%+7.8%1.799% 7/28/2025 TD Asset Management Inc66,906$1.34M0.0%N/A0.136% 7/23/2025 KLP Kapitalforvaltning AS6,800$136K0.0%+58.1%0.014% 6/27/2025 Goldman Sachs Group Inc.211,752$4.17M0.0%+61.3%0.432% 5/29/2025 Rhumbline Advisers52,502$1.03M0.0%+4.9%0.107% 5/19/2025 Jane Street Group LLC29,351$578K0.0%N/A0.060% 5/16/2025 Woodline Partners LP805,157$15.85M0.1%-0.1%1.641% 5/16/2025 Goldman Sachs Group Inc.211,752$4.17M0.0%+61.3%0.432% Trump’s national nightmare is here (Ad)Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.Watch the National Emergency broadcast here5/16/2025 MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.21,729$428K0.0%+8.4%0.044% 5/16/2025 Ally Bridge Group NY LLC169,774$3.34M3.0%+19.8%0.346% 5/16/2025 5AM Venture Management LLC1,322,477$26.03M9.8%-18.9%2.695% 5/16/2025 Adage Capital Partners GP L.L.C.450,000$8.86M0.0%-30.8%0.917% 5/15/2025 Tema Etfs LLC23,648$465K0.1%N/A0.048% 5/14/2025 Quantbot Technologies LP3,043$60K0.0%N/A0.006% 5/14/2025 Wellington Management Group LLP84,700$1.67M0.0%+4.7%0.173% 5/13/2025 Lord Abbett & CO. LLC197,279$3.88M0.0%-48.9%0.402% 5/13/2025 Russell Investments Group Ltd.105,542$2.08M0.0%+148,550.7%0.215% 5/12/2025 Nuveen LLC104,099$2.05M0.0%N/A0.212% 5/12/2025 Invesco Ltd.21,044$414K0.0%+39.6%0.043% 5/9/2025 Deutsche Bank AG27,524$542K0.0%-9.8%0.056% 5/9/2025 Charles Schwab Investment Management Inc.259,537$5.11M0.0%-0.9%0.529% 5/9/2025 Vanguard Group Inc.1,972,239$38.81M0.0%-0.2%4.020% 5/9/2025 BIT Capital GmbH19,386$382K0.0%N/A0.040% 5/8/2025 XTX Topco Ltd21,849$430K0.0%N/A0.045% 5/8/2025 Federated Hermes Inc.69,051$1.36M0.0%-41.3%0.141% 5/1/2025 New York State Common Retirement Fund9,797$193K0.0%-60.8%0.020% 4/30/2025 China Universal Asset Management Co. Ltd.9,800$193K0.0%-5.4%0.020% 4/29/2025 Bank of New York Mellon Corp93,567$1.84M0.0%+4.5%0.191% 4/17/2025 Exchange Traded Concepts LLC6,055$119K0.0%-19.1%0.012% 4/8/2025 Rhumbline Advisers52,502$1.03M0.0%+4.9%0.107% 4/7/2025 GAMMA Investing LLC2,716$53K0.0%+3,058.1%0.006% 3/24/2025 Wellington Management Group LLP80,916$1.82M0.0%+15.3%0.165% 3/18/2025 California State Teachers Retirement System20,914$471K0.0%+10.2%0.043% 2/17/2025 UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC43,714$984K0.0%+67.1%0.089% 2/17/2025 Soleus Capital Management L.P.75,405$1.70M0.1%-68.5%0.154% 2/17/2025 Two Sigma Investments LP14,620$329K0.0%-33.8%0.030% 2/17/2025 Stempoint Capital LP96,716$2.18M0.5%N/A0.198% 2/17/2025 Polar Capital Holdings Plc2,389,668$53.77M0.3%+267.6%4.891% 2/17/2025 ProShare Advisors LLC12,229$275K0.0%+29.5%0.025% 2/17/2025 Patient Square Capital LP224,038$5.04M1.9%+147.4%0.459% 2/17/2025 Nicholas Investment Partners LP157,635$3.55M0.3%-9.3%0.323% 2/17/2025 Millennium Management LLC50,804$1.14M0.0%+108.6%0.104% 2/17/2025 MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.20,036$451K0.0%+3.7%0.041% 2/17/2025 Janus Henderson Group PLC1,331,877$30.00M0.0%+27.9%2.726% 2/17/2025 Graham Capital Management L.P.15,178$342K0.0%+67.3%0.031% 2/17/2025 Deutsche Bank AG30,516$687K0.0%+51.7%0.062% 2/17/2025 Brevan Howard Capital Management LP10,144$228K0.0%N/A0.021% 2/17/2025 Bank of America Corp DE34,187$769K0.0%-29.8%0.070% 2/17/2025 BNP Paribas Financial Markets4,991$112K0.0%N/A0.010% 2/17/2025 Ameriprise Financial Inc.35,059$789K0.0%N/A0.072% 2/17/2025 Ally Bridge Group NY LLC141,710$3.19M2.7%-39.7%0.290% 2/17/2025 5AM Venture Management LLC1,629,765$36.67M8.8%-7.0%3.336% 2/17/2025 Acuta Capital Partners LLC267,368$6.02M6.1%-9.8%0.547% 2/14/2025 Boxer Capital Management LLC671,358$15.11M1.3%N/A1.374% 2/14/2025 RA Capital Management L.P.848,986$19.10M0.3%-20.0%1.738% 2/14/2025 Northern Trust Corp331,500$7.46M0.0%+8.9%0.678% 2/14/2025 Artia Global Partners LP102,900$2.32M0.8%N/A0.211% 2/14/2025 Boothbay Fund Management LLC104,890$2.36M0.1%-21.0%0.215% Trump’s national nightmare is here (Ad)Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.Watch the National Emergency broadcast here2/14/2025 Virtus ETF Advisers LLC3,091$70K0.0%-26.2%0.006% 2/14/2025 Lord Abbett & CO. LLC386,211$8.69M0.0%+20.3%0.790% 2/14/2025 Voya Investment Management LLC10,702$241K0.0%-8.1%0.022% 2/14/2025 Adage Capital Partners GP L.L.C.650,000$14.63M0.0%-18.8%1.330% 2/14/2025 Price T Rowe Associates Inc. MD13,627$307K0.0%+17.0%0.028% 2/14/2025 Tower Research Capital LLC TRC1,598$36K0.0%+230.2%0.003% 2/14/2025 MetLife Investment Management LLC21,746$489K0.0%+6.3%0.045% 2/13/2025 Marshall Wace LLP41,382$931K0.0%-70.0%0.085% 2/13/2025 Barclays PLC64,563$1.45M0.0%+14.8%0.132% 2/13/2025 Legal & General Group Plc21,140$476K0.0%-2.9%0.043% (Data available from 1/1/2016 forward) ELVN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ELVN shares? During the previous two years, 93 institutional investors and hedge funds held shares of Enliven Therapeutics. The most heavily invested institutionals were FMR LLC ($146.16M), Commodore Capital LP ($94.14M), Polar Capital Holdings Plc ($53.77M), Vanguard Group Inc. ($38.81M), Janus Henderson Group PLC ($30.00M), Pictet Asset Management Holding SA ($21.88M), and RA Capital Management L.P. ($19.10M).Learn more on Enliven Therapeutics' institutional investors. What percentage of Enliven Therapeutics' stock is owned by institutional investors? 95.08% of Enliven Therapeutics' stock is owned by institutional investors. Learn more on ELVN's institutional investor holdings. Which institutional investors have been buying Enliven Therapeutics' stock? Of the 74 institutional investors that purchased Enliven Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Polar Capital Holdings Plc ($1.74M), Janus Henderson Group PLC ($908.57K), FMR LLC ($801.30K), Boxer Capital Management LLC ($671.36K), First Turn Management LLC ($535.09K), Marshall Wace LLP ($514.27K), and TCG Crossover Management LLC ($498K). How much institutional buying is happening at Enliven Therapeutics? Institutional investors have bought a total of 9,316,124 shares in the last 24 months. This purchase volume represents approximately $207.52M in transactions. Which of Enliven Therapeutics' major shareholders have been selling company stock? Of the 38 institutional investors that sold Enliven Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: RA Capital Management L.P. ($1.27M), 5AM Venture Management LLC ($979.70K), Adage Capital Partners GP L.L.C. ($704K), Lord Abbett & CO. LLC ($188.93K), Soleus Capital Management L.P. ($164.30K), Acuta Capital Partners LLC ($130.33K), and Federated Hermes Inc. ($101.45K). How much institutional selling is happening at Enliven Therapeutics? Institutional investors have sold a total of 4,074,071 shares in the last 24 months. This volume of shares sold represents approximately $90.81M in transactions. Related Companies TG Therapeutics Institutional Ownership Cytokinetics Institutional Ownership Ascentage Pharma Group International Institutional Ownership Krystal Biotech Institutional Ownership ACADIA Pharmaceuticals Institutional Ownership ADMA Biologics Institutional Ownership Telix Pharmaceuticals Institutional Ownership Vaxcyte Institutional Ownership PTC Therapeutics Institutional Ownership Lantheus Institutional Ownership This page (NASDAQ:ELVN) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
